J. Lipid Res. Neurobiology of Lipids (ISSN1683-5506)
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1194/jlr.M400052-JLR200 on December 1, 2004

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
M400052-JLR200v1
46/3/445    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by van Himbergen, T. M.
Right arrow Articles by van Tits, L. J. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by van Himbergen, T. M.
Right arrow Articles by van Tits, L. J. H.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Journal of Lipid Research, Vol. 46, 445-451, March 2005
Copyright © 2005 by American Society for Biochemistry and Molecular Biology

Indications that paraoxonase-1 contributes to plasma high density lipoprotein levels in familial hypercholesterolemia

Thomas M. van Himbergen1,*,{dagger}, Mark Roest*, Jacqueline de Graaf{dagger}, Eugène H. J. M. Jansen§, Hiroaki Hattori**, John J. P. Kastelein{dagger}{dagger}, Hieronymus A. M. Voorbij*, Anton F. H. Stalenhoef{dagger} and Lambertus J. H. van Tits{dagger}

* Research Laboratory of the Department of Clinical Chemistry, University Medical Center Utrecht, Utrecht, The Netherlands
{dagger} Department of Medicine, Division of General Internal Medicine, University Medical Center Nijmegen, Nijmegen, The Netherlands
§ Laboratory for Toxicology, Pathology, and Genetics, National Institute for Public Health and the Environment, Bilthoven, The Netherlands
** Department of Advanced Medical Technology and Development, BML, Inc., Saitama 350-1101, Japan
{dagger}{dagger} Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands

1 To whom correspondence should be addressed. e-mail: t.m.vanhimbergen{at}lab.azu.nl

HDL-associated paraoxonase type 1 (PON1) can protect LDL and HDL against oxidative modification in vitro and therefore may protect against cardiovascular disease. We investigated the effects of PON1 levels, activity, and genetic variation on high density lipoprotein-cholesterol (HDL-C) levels, circulating oxidized LDL (OxLDL), subclinical inflammation [high-sensitive C-reactive protein (Hs-CRP)], and carotid atherosclerosis. PON1 genotypes (L55M, Q192R, –107C/T, –162A/G, –824G/A, and –907G/C) were determined in 302 patients with familial hypercholesterolemia. PON1 activity was monitored by the hydrolysis rate of paraoxon, diazoxon, and phenyl acetate. PON1 levels, OxLDL, and Hs-CRP were determined using an immunoassay. The genetic variants of PON1 that were associated with high levels and activity of the enzyme were associated with higher HDL-C levels (P values for trend: 0.008, 0.020, 0.042, and 0.037 for L55M, Q192R, –107C/T, and –907G/C, respectively). In addition to the PON1 genotype, there was also a positive correlation between PON1 levels and activity and HDL-C (PON1 levels: r = 0.37, P < 0.001; paraoxonase activity: r = 0.23, P = 0.01; diazoxonase activity: r = 0.29, P < 0.001; arylesterase activity: r = 0.19, P = 0.03).

Our observations support the hypothesis that both PON1 levels and activity preserve HDL-C in plasma.

Abbreviations: CCA-IMT, common carotid artery intima-media thickness; CVD, cardiovascular disease; FH, familial hypercholesterolemia; HDL-C, high density lipoprotein-cholesterol; Hs-CRP, high-sensitive C-reactive protein; LDL-C, low density lipoprotein-cholesterol; OxLDL, oxidized low density lipoprotein; PON1, paraoxonase type 1

Supplementary key words atherosclerosis • antioxidants • polymorphisms


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Clin. Chem.Home page
B. Thyagarajan, D. R. Jacobs Jr., J. J. Carr, O. Alozie, M. W. Steffes, P. Kailash, J. H. Hayes, and M. D. Gross
Factors Associated with Paraoxonase Genotypes and Activity in a Diverse, Young, Healthy Population: The Coronary Artery Risk Development in Young Adults (CARDIA) Study
Clin. Chem., April 1, 2008; 54(4): 738 - 746.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
L. Gaidukov and D. S. Tawfik
The development of human sera tests for HDL-bound serum PON1 and its lipolactonase activity
J. Lipid Res., July 1, 2007; 48(7): 1637 - 1646.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
M.-C. Blatter Garin, X. Moren, and R. W. James
Paraoxonase-1 and serum concentrations of HDL-cholesterol and apoA-I
J. Lipid Res., March 1, 2006; 47(3): 515 - 520.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
R. J. Bisoendial, G. K. Hovingh, K. El Harchaoui, J. H.M. Levels, S. Tsimikas, K. Pu, A. E. Zwinderman, J. A. Kuivenhoven, J. J.P. Kastelein, and E. S.G. Stroes
Consequences of Cholesteryl Ester Transfer Protein Inhibition in Patients With Familial Hypoalphalipoproteinemia
Arterioscler. Thromb. Vasc. Biol., September 1, 2005; 25(9): e133 - e134.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Journal of Biological Chemistry 
 Molecular and Cellular Proteomics   ASBMB Today 
Copyright © 2005 by the American Society for Biochemistry and Molecular Biology.